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Abstract: The population in developed countries is ageing
and the number of people experiencing joint-related condi-
tions, such as osteoarthritis, is expected to increase. Joint
replacements are currently the most effective treatment for
severe joint conditions and although many of these proce-
dures are successful, infection developing after the procedure
is still an issue, requiring complex and expensive revisions.
Whilst incorporating a powdered antibiotic within the bone
cement can reduce infection rates, the powder frequently
agglomerates, resulting in poor antibiotic release characteris-
tics and compromised mechanical performance of the
cement. To overcome these issues, a novel delivery system
consisting of antibiotic-loaded nano-sized liposomes was
developed for inclusion into polymethyl methacrylate
(PMMA) bone cement. This system was tested in a commer-
cial cement (Palacos R) and consistently delivered a higher
percentage (22%) of the incorporated antibiotic when com-
pared to the powdered antibiotic cement (9%), meaning less
antibiotic needs to be incorporated than with conventional
cement. The novel system resulted in a controlled and grad-
ual release of antibiotic over a longer, 30-day period and
enhanced the toughness, bending strength and Vickers hard-
ness of the cement, without altering its polymerization or
molecular structure. This new material has the potential to
significantly reduce infections in cemented joint replace-
ments leading to enhanced patient quality of life and reduced
healthcare costs. VC 2015 Wiley Periodicals, Inc. J Biomed Mater Res
Part B: Appl Biomater, 00B: 000–000, 2015.
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INTRODUCTION
Polymethyl methacrylate (PMMA) bone cements have been
widely employed in hip and knee replacements since their
introduction by Sir John Charnley in 1953.1,2 In England
and Wales 178,000 hip and knee replacements, of which
102,700 were cemented, were performed in 2012, a 300%
increase since 2004.3 Bone cement has several roles: to
secure the implant in place; to distribute stresses between
the stiff metallic implant and the bone; and, frequently, to
prevent infection by releasing an antibiotic. The latter role
was ﬁrst developed in 1969 when Buchholz et al.4 observed
that the monomer of bone cement was eluted over long
periods of time after setting. This led to the concept of local
delivery of powdered antimicrobial agents from bone
cement. The most successful of the antimicrobial agents
tested is gentamicin sulfate, a broad spectrum antibiotic,
which is currently employed in several commercial bone
cements. Gentamicin is an aminoglycoside antibiotic that
inhibits protein synthesis by binding to the 30S ribosome
subunit of bacteria.5 Gentamicin is available as a dry
powder and is heat stable, making it ideal for the high set-
ting temperatures of bone cement.5,6
Localised release of antibiotic is imperative for joint
replacements as systemic treatment is ineffective due to the
limited circulation in the area adjacent to the implant.
Incorporating a powdered antibiotic in bone cement has
proved to be successful, resulting in a reduction in primary
implant infection rates from 7% to lower than 1%.7 In a
recent survey conducted by the National Joint Registry for
England and Wales it was shown that between 2003 and
2010, there has been an increase from 85% to 93% and 92
to 97%, respectively in the percentage of antibiotic-loaded
bone cement used for primary hip and knee replacements.8
This trend not only demonstrates the perceived success of
this particular technique but also reﬂects a growing desire
to prevent post-surgical infections in joint replacements.
Infected joint replacements are difﬁcult to treat and require
the complete removal of the cement and implant. This pro-
cedure is costly for both patients and health services due to
its complexity, high risk and poor surgical outcome.9
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Although the use of gentamicin sulfate powder in PMMA
bone cement has been successful in reducing the rate of infec-
tions in hip and knee replacements, 2,500 revision procedures
were still required in the UK in 2012 due to infection3 and
22,000 revisions of infected hip and knee replacements
were performed in the US in 2009.10 These ﬁgures are pro-
jected to increase, as are the costs associated with this com-
plex procedure.3,10–12 Furthermore, there are concerns that
the antibiotic powder may have a detrimental effect on the
mechanical properties of the cement. Commercial cements
employ 0.5–1 g of gentamicin sulfate per 40 g of cement and
this can cause signiﬁcant reductions in mechanical and fatigue
properties of the cement.13–16 The powdered antibiotic is
poorly dispersed and agglomerated in the cement and, as a
result, only a small percentage of the incorporated gentamicin
sulfate is released, the majority in an uncontrolled burst from
surface agglomerations within the ﬁrst few hours.14 Sub-
inhibitory concentrations are thought to be released there-
after, which may encourage the establishment of an antibiotic-
resistant bacterial population.17
To overcome these problems we propose the use of lipo-
somes to disperse therapeutic agents within bone cement
and to control their release characteristics. Liposomes are
spherical vesicles composed of lipid molecules that are
capable of encapsulating a variety and combination of both
hydrophilic and hydrophobic therapeutic agents. The struc-
ture, size and composition of the liposome can be tailored
for speciﬁc applications. Liposomes have been extensively
used in medicine for the treatments of infections, cancers,
pain management, vaccinations and in ophthalmology.18–20
Various therapeutic agents have been incorporated within
liposomes, including antimicrobial and antineoplastic thera-
peutic agents, chelating agents, steroids, vaccines and
genetic materials.21 The majority of these liposomal systems
are administered as an aqueous suspension and there is lit-
tle evidence of their use in polymers or non-aqueous envi-
ronments; the hydrophilic head groups on the outermost
layer of the liposome are generally not compatible with
hydrophobic materials, such as PMMA bone cements. Due to
the hydrophobicity of methyl methacrylate, phase separation
of the aqueous lipid suspension is likely to occur. For this
reason, the use of gentamicin solution in the liquid compo-
nent of bone cements has also proven unsuccessful as sig-
niﬁcant reductions in mechanical properties were
observed.22,23 This was found to occur as a result of the
water content and phase separation increasing the size and
number of pores. This problem severely limits the range of
antibiotics and other drugs that can be incorporated in the
cement. To overcome the issue of phase separation, surfac-
tants may be used. Miller et al. attempted to use surfactants
with gentamicin solution but found reductions in mechani-
cal properties nevertheless due to the presence of water.24
Pelleted liposomes, obtained through ultra-centrifugation in
conjunction with amphiphilic polymers (containing a hydro-
phobic and a hydrophilic portion) may overcome this issue.
Non-toxic, neutral surfactants, such as Pluronic block
copolymers, which improve the miscibility of solutions, may
be employed to overcome phase separation of the liposomes
in methyl methacrylate. Pluronics consist of two hydrophilic
polyethylene oxide (PEO) chains connected by a hydropho-
bic polypropylene oxide (PPO) chain (PEO-PPO-PEO).
The aim of this study was to incorporate gentamicin sul-
fate into 100 nm extruded liposomes, coated with Pluronics,
within the liquid component of a commercial bone cement,
Palacos R. The dispersion of the liposomes was studied in
methyl methacrylate and within the polymerised cement.
Release characteristics, antibacterial activity and mechanical
and fatigue properties were evaluated.
MATERIALS AND METHODS
Liposome preparation
Phosphatidylcholine (PC) from egg yolk (99%), cholesterol
(C, 99), gentamicin sulfate (590 mg gentamicin base per
mg) and Pluronics L31 and L61 were purchased from Sigma
Aldrich (Sigma-Aldrich Company Ltd., Gillingham, UK). Plur-
onic L43 was provided by BASF (BASF Corporation, Con-
necticut, USA); chloroform (HPLC grade) was purchased
from Fisher Scientiﬁc (Fisher Scientiﬁc UK, Loughborough,
UK). 175 mg of PC and 25 mg of C (weight ratio of 7:1)
were weighed and dissolved with 5 mL of chloroform in a
50 mL round bottom ﬂask. The chloroform was evaporated
using a rotary evaporator at 608C (above the phase transi-
tion temperature of PC) under vacuum. The lipid bilayer
was resuspended in 40 mL of 5 mg mL21 gentamicin sulfate
solution by vortex mixing. The suspension was then held at
608C for 30 min prior to 10 extrusions under nitrogen pres-
sure (8 bars maximum) using a Lipex extruder (Northern
Lipids, British Columbia, Canada) vertically through a
400 nm polycarbonate membrane (Whatman, UK). The sus-
pension was subsequently extruded a further 10 times
through a 100 nm polycarbonate membrane. Average lipo-
some diameter was determined by photon correlation spec-
troscopy (Beckman Coulter N4 PLUS). L31 Pluronic (2%w/
w) was added and the suspension centrifuged at 100,000 g
(25,000 RPM) for 1 hr at 48C (Beckman Optima LE-80K) to
create a pellet. The 200-mg pellet was resuspended in
20 mL of the liquid MMA component of Palacos R) by the
process of titruration. The method was repeated for L43
and L61 Pluronics. These Pluronics were employed as they
created the most stable liposome suspensions in terms of
sedimentation rate and dispersion.25
Transmission electron microscopy
Uranyl acetate (98.0%) and methyl methacrylate
(98.5%) with 30 ppm hydroquinone were purchased
from Sigma–Aldrich (Sigma–Aldrich Company., Gillingham,
UK). Transmission electron microscopy (TEM) was used to
image the dispersion of liposomes in MMA and water.
100 mg of PC:C liposomes and 100 mg of PC:C liposomes
with L61 Pluronic were prepared as described in the Lipo-
some Preparation section at 5 mg mL21 concentration,
mixed with an equal volume of 4%w/v aqueous uranyl ace-
tate solution and incubated for 60 min. The liposomes were
centrifuged into 20 mg pellets and resuspended into 20 mL
of water or MMA. Ten mL of the diluted suspension was
placed on a Formvar carbon ﬁlm on a 400 mesh Nickel grid
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(EM Systems Support, Macclesﬁeld, UK) and allowed to dry
in air. MMA alone was also dried on a grid as a control.
Grids were visualised using a Philips CM12 TEM (Philips
Research, Eindhoven, Netherlands) operating at 80 kV.
Images were recorded using an SIS MegaView III digital
camera (Olympus Soft Imaging Solutions GmbH, M€unster,
Germany).
Fluorescent microscopy
To assess the dispersion of the liposomes in a commercial
cement, 16 mL of a 5 mg mL21 liposome suspension in
water was prepared as described in the Liposome Prepara-
tion section, however ﬂuorescent TopFluor cholesterol (FC;
23-(dipyrrometheneboron diﬂuoride)-24-norcholesterol;
INstruchemie BV, Delfzijl, Netherlands) was used to substi-
tute for a portion of the cholesterol component to give a
weight ratio of 7:0.9:0.1 of PC:C:FC. The suspension was
divided into four aliquots of 4 mL. A 2%w/w of Pluronic
L31, L43, or L61 was added to three of the aliquots and the
suspension was centrifuged as previously described. Simi-
larly, the remaining 4-mL aliquot of the liposomal suspen-
sion alone was also centrifuged. The four 20 mg pellets
were individually resuspended in 2 mL of the liquid MMA
component of Palacos R (Heraeus Medical, Newbury, UK).
This was mixed with 4 g of the Palacos R powder as out-
lined by the ISO5833 guidelines and the cement manufac-
turer’s instructions.26 After mixing the cement was
compressed between two glass slides to create a thin sam-
ple capable of transmitting light. All cement samples were
stored in the dark until observed using an Olympus IX50
ﬂuorescent microscope.
Detection of structural changes using FTIR
Fourier Transform Infrared Spectroscopy (FTIR) was
employed to detect changes in the polymer structure due to
the presence of the liposomes. Palacos R, Palacos R1G and
the liposomal Palacos R cement with L61 Pluronic were
scanned using attenuated total reﬂectance (ATR) with a Per-
kin Elmer Spectrum One FT-IR Spectrometer with FT-IR
Spectrum software (Perkin Elmer, Massachusetts, USA)
between 4000 and 450 cm21 with a resolution of 4 cm21.
The surface of the cement samples were scanned at six dif-
ferent sections on the sample, taking 30 scans at each sec-
tion to obtain an average spectrum.
Antibiotic release
O-phthaldialdehyde (97%, HPLC), ethanol (99.8%,
HPLC), 2-mercaptoethanol (99.0%) and sodium borate
(99.0%) were purchased from Sigma Aldrich (Sigma–
Aldrich Company, Gillingham, UK). Sodium chloride
(99.9%), potassium chloride (99%), calcium chloride
(99%), and sodium bicarbonate (99.7%) were purchased
from Fisher Scientiﬁc (Fisher Scientiﬁc UK, Loughborough,
UK). Palacos R and Palacos R1G cements (Heraeus Medical,
Newbury, UK) with or without liposomes were mixed as
outlined in the manufacturer’s instructions and the ISO5833
guidelines.26 Table I shows the compositions of the cements
tested. An ultra-high molecular weight PTFE mould was
manufactured to produce 10 mm diameter by 2-mm thick
cylindrical samples. All samples were abraded with a 250
grit silicon carbide paper to the stated dimensions with a
tolerance of 60.2 mm. Each sample weighed 0.406 0.01 g
and ﬁve samples for each test group were examined. Each
sample was stored in 5 mL of Ringer’s solution (8.6
mg mL21 NaCl, 0.3 mg mL21 KCl and 0.33 mg mL21 CaCl2,
buffered to a pH of 7.4 with NaHCO3
27) at 378C. After 6 hr,
1, 2, 3, 7, 15, 30, and 60 days the Ringer’s solution was
removed and stored in the dark at 2208C before assaying;
5 mL of fresh Ringer’s was added as replacement. Ringer’s
solution was replaced at the selected time points in order
to approach sink conditions, a condition where the drug
concentration in the eluent can be assumed negligible in
comparison to the maximum solubility of the drug (50
mg mL21 for gentamicin sulfate).
The solutions were thawed overnight at room tempera-
ture in the dark and the concentration of gentamicin
released was determined using an o-phthaldialdehyde (PHT)
method developed by Sampath et al.28 and Zhang et al.,29
whereby a PHT reagent reacts with the amino groups of
gentamicin sulfate to yield measurable ﬂuorogenic products.
The reagent was prepared by adding 2.5 g of o-
phthaldialdehyde, 62.5 mL of ethanol and 3 mL of 2-
mercaptoethanol to 560 mL of 0.04M sodium borate
TABLE I. Composition of Palacos R, Palacos R1G, and the Liposomal Palacos R Cements
Palacos R Palacos R1G
Liposomal Palacos R
(L31/L43/L61)
Liquid Total liquid g 18.78 18.80 18.80
Methyl methacrylate %w/w 97.98 97.87 97.88
N,N dimethyl-p-toluidine %w/w 2.02 2.13 2.02
Hydroquinone ppm 60.00 60.00 60.00
Liposomal gentamicin sulfate (200mg)/%w/w – – 0.11
Powder Total powder g 40.00 40.80 40.00
Poly(methyl methacrylate/methyl acrylate) %w/w 84.50 83.27 84.50
Zirconium dioxide %w/w 15.00 15.00 15.00
Benzoyl peroxide %w/w 0.50 0.50 0.50
Gentamicin sulfate (590 mg gentamicin
base per mg) %w/w
– 1.23 –
Powder: Liquid ratio 2.13 2.17 2.13
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solution in distilled water. The PHT reagent was stored in
an amber glass bottle in the dark for 24 hr prior to use.
1 mL of the sample eluate was mixed with 1 mL PHT
reagent and 1 mL isopropanol and left for 40 min to react
and its absorbance compared against a gentamicin calibra-
tion curve (ranging from 0 to 100 lg mL21), in order to
determine the concentration of gentamicin released by the
samples at each time point. Average gentamicin concentra-
tions for each time point were calculated from the ﬁve sam-
ples and the gentamicin release was determined as a
percentage of the theoretical maximum amount of gentami-
cin sulfate in each sample.
Mathematical modelling of release
Mathematical models were applied to the antibiotic release
data for the commercial bone cements in order to better
understand the release kinetics. In the equations described,
Rt is the total percentage gentamicin sulfate released, t is
the time period, n is an exponential function and k is a dif-
fusion related constant. Equation (1) was developed by
Korsmeyer et al.30 who stated drug release was exponen-
tially related to time.
Rt5 kt
n (1)
Higuchi et al.31 proposed Eq. (2), whereby the release of
drugs is dependent upon Fickian diffusion of water into the
material.
Rt5 kt
1=2 (2)
Equation (3) is associated with a Noyes–Whitney disso-
lution process.32 The Noyes–Whitney dissolution process
states that the dissolution rate of a solid is dependent on its
diffusion coefﬁcient, the surface area of the solid, the con-
centration at the boundary layer and the length of the
boundary layer.
Rt5 k 12exp 2ntð Þ½  (3)
Equation (4) is an expanded version of Korsmeyer’s
work developed by Lindner and Lippold33 which takes into
account an additional coefﬁcient (b) to represent the initial
burst of antibiotics from the surface of the cement. The
additional coefﬁcient was added to the Higuchi and Noyes–
Whitney equations [Eqs. (1) and (3)] and applied to the
release data.
Rt5b1kt
n (4)
All models were applied to the data using the curve ﬁt-
ting toolbox in Matlab (MathWorks, Cambridge, MA), which
calculates the coefﬁcients by minimizing the sum of squared
residuals.
Agar diffusion assay
Three 10 mm diameter by 2 mm thick cylindrical samples
of Palacos R, Palacos R1G, and the liposomal Palacos R
cements (L31, L43, and L61) were prepared as previously
described in the Liposome Preparation section. Staphylococ-
cus aureus (S. aureus, NCIMB 9518) was cultured in tryp-
tone soya broth (TSB) for 18–24 hr at 378C. A sterile cotton
swab was used to spread the inoculum across the TSA Petri
dish. The Petri dish was turned through 608 and the process
was repeated to ensure complete surface coverage. A 10 mg
gentamicin disc (Oxoid, Hampshire, UK) was placed on the
Petri dish as a control and pressure was applied to the top
of the disc to ensure full surface contact. The dish was
divided into segments and the bone cement samples were
individually placed into each segment well separated on the
agar, in the same manner. The Petri dish was then incubated
at 378C for 24 hr, after which, the zones of inhibition around
the samples and gentamicin disc were measured. Images of
the zones of inhibition were taken and analyzed using
ImageJ software (National Institutes of Health, MA). The
zones of inhibition were measured as the radius of the zone
minus the radius of the sample. Two measurements for
each zone of inhibition were taken, perpendicular to one
another and the experiment was repeated in triplicate
(n5 3).
Mechanical properties
The compression and bending properties of Palacos R, Pala-
cos R1G, and the liposomal Palacos R cement samples were
determined using a Zwick Roell ProLine table-top Z050/
Z100 materials testing machine with TestXpert II software
(Zwick Testing Machines, Herefordshire, UK) following the
ISO5833 standard.26 Cylindrical compression samples
(6 mm diameter and 12 mm length) were tested at a cross-
head speed of 20 mm min21. Rectangular bending samples
(75 mm length, 10 mm width, and 3.3 mm thickness) were
tested at a cross-head speed of 5 mm min21 in four-point
bending. Five compression and ﬁve bending samples were
tested to determine average compression and bending
properties.
Fracture toughness
Linear elastic fracture mechanics (LEFM) was used to deter-
mine the fracture toughness of cement samples. Fractured
bending samples were employed for single-edge notched
three-point bending (35 mm length, 10 mm width, and
3 mm thickness). A sharp chevron notch (4.5–5.5 mm in
length) was created through the center of the sample using
a surgical scalpel blade mounted onto a modiﬁed micro-
tome, as described by Evans et al.34 and the initial crack
length and specimen dimensions were measured using a
travelling microscope (Pye Scientiﬁc, Cambridge, UK). The
specimens were loaded at a crosshead speed of 5
mm min21 in three-point bending, with the span between
the rollers set to 40 mm, until failure occurred. The load
and displacement were recorded and the critical stress
intensity factor (Kic) of the cement was calculated as
described in the ISO13586:2000 standard.35 Five samples
were tested for each group to produce mean fracture tough-
ness values.
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Glass transition temperature
The glass transition temperature of Palacos R, Palacos R1G,
and the liposomal Palacos R cements were determined by
dynamic mechanical analysis using a Rheometric Scientiﬁc
V500 (TA Instruments, Elstree, UK). Small matchstick-like
samples (30 mm length, 3 mm width, and 2 mm height)
were prepared and loaded sinusoidally at a frequency of 1
Hz in a dual cantilever conﬁguration whilst heated from 358C
to 2008C at a rate of 108C min21 with the applied stress and
strain measured. The phase lag (d) between the stress (r)
and strain (e) was measured and the storage modulus (E0)
and loss modulus (E00) were calculated using Eqs. (5) and (6)
respectively. The complex viscosity (tan d) was calculated as
shown in Eq. (7) and plotted against temperature. The tem-
perature at which tan d was at its maximum was considered
to be the glass transition temperature (Tg). Five samples
were tested to obtain a mean value for Tg.
E’ 5
r
e
cos d (5)
E 5
r
e
sin d (6)
tan d5
E0
E00
(7)
Vickers hardness
Palacos R, Palacos R1G and the liposomal Palacos R cement
disc shaped samples (10 mm diameter and 2 mm height)
were prepared and the surfaces polished with a 4000 grit
silicon carbide paper. The microhardness of the samples
was tested according to the ISO6507-2 standard.36 Five
indentations, 1 mm apart and 1 mm from the edges of the
sample, were placed on both sides of each sample using a
Zwick 3212 indenter ﬁtted with a 1368 square-based pyra-
mid diamond indenter (Zwick Testing Machines Ltd., Here-
fordshire, UK) with a load of 200 g for 10 s. Indentations in
the vicinity of large pores (>50 mm) were disregarded and
repeated. For each indentation, two diagonal lengths were
measured using a travelling microscope and averaged. Equa-
tion (8) was employed to calculate the average hardness
value (in MPa), where F is the load in kg (0.2) and d is the
mean diagonal length of the indentation in mm.
Hardness 5 1:854 3
F
d2
(8)
Fatigue
Fatigue crack growth tests were performed using disc com-
pact tension (DCT) specimens, with dimensions conforming to
the ASTM E399 standard37 as described by Evans et al.34 A
modiﬁed microtome was used to cut a chevron notch, which
ensured symmetrical crack growth. The initial crack length
and specimen dimensions were measured using a travelling
microscope (Pye Scientiﬁc, Cambridge, UK). To apply the load
symmetrically across the sample, loose plates with oversize
holes were employed, which allowed the loading pins to
rotate freely without friction. The crack length was monitored
using Krak-gauges and a constant current supply and
ampliﬁer designed and built by Evans et al.34 was used to
obtain accurate crack growth measurements at low crack
growth rates. Precision components were employed and the
current regulator and preampliﬁer were kept at a constant
temperature in an Instron environmental chamber (Instron
SFL, Bristol, UK) to achieve very low noise and offset drift.
Two fatigue samples for Palacos R, Palacos R1G and the
liposomal Palacos R cements were tested. All tests were car-
ried out in an Instron environmental chamber at 378C using
a 5 kN Dartec servohydraulic testing machine with an MTS
FlexTest GT controller and MTS Multipurpose software
(MTS, Eden Prairie, MN).
Samples were cyclically loaded in load control with a sine
wave at 5 Hz between 100N and 10N (R-ratio of 0.1), allowing
for measurements of crack growth rates through stress inten-
sities of 0.3 to 0.9 MPam1/2. Prior to loading, samples were
subject to a precracking procedure to ensure an initial steady
crack growth rate of 1029m/cycle. For precracking, a high
cyclic load of 200 N at 5 Hz was applied and the load reduced
by 10% after every 0.2 mm of crack growth. The crack length
and number of cycles were measured during loading and the
crack growth rate (da/dN in m/cycle) was calculated for every
0.2 mm of crack growth. Similarly, the corresponding stress
intensity factor range (DK) for each sample and crack length
(ranging from 6 to 12 mm, in steps of 0.2 mm) was calculated
using Eq. (9), where Pmax is the maximum load, Pmin is the
minimum load, b is the sample thickness, a is the crack length
from the center point of the holes to the tip of the crack, W is
the width of the specimen from the center point of the holes
to the bottom of the specimen and a is a/W and is >0.2.
DK 5
ðPmax2PminÞ
b
ﬃﬃﬃﬃ
w
p 3 ð21aÞ
1 – að Þ3=2
0:7614:8a211:58a2111:43a324:08a4
 
(9)
For each sample, da/dn was plotted as a function of DK
on a logarithmic scale. The Paris Law was applied to obtain
coefﬁcients “A” and “m” [as shown in Eq. (10)] for each
sample group.
da
dn
5 A DKm (10)
Scanning electron microscopy
The fracture surfaces of the fatigue testing samples were
gold coated using an E65x sputter coater (Emitech, Kent,
UK) and imaged using an EBT1 scanning electron micro-
scope (SEM Tech, Southampton, UK) at 15 KeV. Similarly,
the surfaces of the antibiotic release samples were imaged
to study surface porosity.
Statistical analysis
An analysis of variance (ANOVA) was carried out to estab-
lish signiﬁcant differences between groups of samples using
the data analysis package in Excel (Microsoft, Reading, UK).
Signiﬁcance between groups was deﬁned as those with a
calculated p values of <0.05.
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RESULTS
Liposome diameter (with and without Pluronics in
water)
Prior to extrusion the average diameter of the liposomes was
5886 243 nm. After 10 extrusions through a 400 nm polycar-
bonatemembrane and 10 extrusions through a 100 nmpolycar-
bonate membrane, the average diameter of the liposomes was
1006 19 nm. After ultra-centrifugation and resuspension, the
diameter was 111616 nm. The addition of Pluronics L31, L43,
and L61 did not alter the average diameter of the liposomes
(1086 28 nm, 106621 nm, and 101630 nm, respectively).
Transmission electron microscopy (TEM)
Figure 1 shows TEM images of liposomes with and without
the addition of Pluronic L61 resuspended in water or MMA.
After centrifugation and resuspension the individual lipo-
somes were intact and approximately 100 nm in diameter,
demonstrating that centrifugation at 100,000g for 1 hr did
not damage the lipid bilayer and conﬁrming the results
obtained by photon correlation spectroscopy. Small agglomer-
ations were observed when liposomes were resuspended in
water after centrifugation [Figure 1(a)], whilst large agglom-
erations were observed when the liposomes with Pluronic
L61 were resuspended in water [Figure 1(b)]. When resus-
pending the liposomes in MMA without Pluronic L61, the lip-
osomes were found to coalesce potentially due to the
hydrophilic interactions between the polar heads of the phos-
pholipids in the hydrophobic MMA [Figure 1(c)]. Improved
dispersion was achieved however when liposomes with Plur-
onic L61 were resuspended in MMA [Figure 1(d)]. Individual
liposome diameters were ~100 to 200 nm, conﬁrming the
results observed by photon correlation spectroscopy.
Fluorescence microscopy
The ﬂuorescent liposome pellets were resuspended in the
liquid component of Palacos R bone cement prior to
FIGURE 1. TEM images of liposomes in (a) water and (b) MMA and liposomes with Pluronic L61 in (c) water, (d) MMA (Bar5 1 mm) and (e) lipo-
somes with Pluronics L61 in MMA at a lower magnification.
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combination with the powder component and polymeriza-
tion. Figure 2 shows ﬂuorescent microscopy images of the
cement surfaces containing liposomes with and without
Pluronics L31, L43, and L61. Similar results to the TEM
images were observed; when resuspending liposomes with-
out Pluronics in Palacos R cement, high levels of agglomera-
tion were observed [Figure 2(a)]. The Pluronics were found
to enhance the dispersion of the liposomes throughout the
cement [Figure 2(b–d)].
Detection of structural changes using FTIR
FTIR was employed to detect potential changes in polymer-
ization or cement structure arising from incorporating lipo-
somes. Figure 3 shows the FTIR spectra for Palacos R,
Palacos R1G and liposomal Palacos R with L61 Pluronic
using attenuated total reﬂectance. FTIR peaks representative
of PMMA were observed in all samples. These peaks were:
between 2850 and 2950 cm21 for methylene (CH2) and
methyl (CH3) stretches; between 1300 and 1500 cm
21 for
the CH bend; at 1400 and 1450 cm21 for methyl groups
(CH3); at 1240 cm
21 for the CACAO stretch; at 1140 cm21
for the OACAC stretch; at 1730 cm21 for the C@O stretch;
and between 1300 and 900 cm21 for the CAO stretch.
Broad bands were observed at ~3448 cm21 and sharp
bands at 1636 and 1051 cm21 for Palacos R1G and Palacos
R with liposomes due to the presence of gentamicin sulfate.
No other differences were observed between all three
cements, demonstrating the liposomes did not interact or
alter the polymerization or structure of Palacos R.
FIGURE 2. Fluorescence microscopy images of fluorescent liposomes (a) without coating and with Pluronics (b) L31, (c) L43, and (d) L61 in Pala-
cos R cement (Bar5 100 mm). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 3. FTIR spectra of Palacos R, Palacos R1G and liposomal Pal-
acos R with Pluronic L61 using attenuated total reflectance (ATR).
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Antibiotic release
A strong linear correlation was obtained between gentami-
cin sulfate concentration and absorbance at 340 nm using
the o-phthaldialdehyde method (R value of 0.9987), with
acceptable standard deviations up to gentamicin sulfate con-
centrations of 90 lg mL21 (absorbance of 1.6). The percent-
age antibiotic release from Palacos R, Palacos R1G and the
liposomal Palacos R cements with L31, L43, and L61 Plur-
onics after 72 hr and 1440 hr are shown in Figure 4(a,b),
respectively. The liposomal Palacos R cements performed
more efﬁciently than the Palacos R1G. At 6 hr, a similar
percentage release was experienced by Palacos R1G and
the liposomal Palacos R cements (’2.7%), however after
this time the liposomal Palacos R cements achieved much
higher percentages. At 72 hr, the liposomal Palacos R
released 11–12% of the total gentamicin sulfate used, whilst
Palacos R1G released ~6%. Over the ﬁrst 72 hr gentamicin
release from the liposomal Palacos R cements was more lin-
ear than the Palacos R1G, which experienced an initial
burst of release followed by lower levels of release there-
after [Figure 4(a)]. Furthermore, the standard deviations
experienced for all liposomal Palacos R cements within the
ﬁrst 72 hr were less than those of the commercial Palacos
R1G cement containing powdered gentamicin. After 1440
FIGURE 4. Total percentage gentamicin sulfate release for Palacos R,
Palacos R1G and the liposomal Palacos R cements over (a) 72 hr and
(b) 1440 hr. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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hr, the liposomal Palacos R cements had released 21-22% of
the incorporated gentamicin, more than Palacos R1G [8.9%,
Figure 4(b)].
Mathematical modelling of release
The results from the mathematical modelling of the genta-
micin sulfate release from Palacos R1G and the liposomal
Palacos R cement are shown Table II. Coefﬁcient values
(k, n, and b) that most accurately model the experimental
antibiotic release data are shown. The table also shows the
goodness of ﬁt (R value) between the experimental data and
the models.
For all cements, the n-coefﬁcient for the Korsmeyer–Pep-
pas model was found to be <0.5, demonstrating that the
release of gentamicin sulfate from the cements was not gov-
erned by Fickian diffusion alone. The Higuchi model for the
FIGURE 5. Zones of inhibition for S. aureus on tryptone soya agar. S. aureus was susceptible to 10 mg of gentamicin (a), whilst Palacos R alone
was not antimicrobial (b). Palacos R1G demonstrated inconsistent zones of inhibition (c), whilst the liposomal Palacos R cements consistently
inhibited S. aureus growth around the cement (d–f). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
TABLE III. Mechanical Properties and Fracture Toughness for Palacos R, Palacos R1G, and the Liposomal Palacos Cements
with L31, L43, and L61 Pluronics
Compressive
Strength
(MPa)
Bending
Strength
(MPa)
Bending
Modulus
(MPa)
Fracture
Toughness
(MPam1/2)
Glass Transition
Temperature
(8C)
Vickers
Hardness
(MPa)
Palacos R 104.66 2.6 73.46 2.9 34606 97 2.560.2 126.26 3.3 19.86 1.8
Palacos R1G 95.76 3.3a 66.66 2.4a 31106 110a 2.560.1 115.46 1.2a 18.76 1.8
Palacos R L31 80.86 3.4a,b 79.06 3.9b 32006 61a 3.060.3a,b 122.76 2.2b 26.66 3.2a,b
Palacos R L43 77.46 2.4a,b 73.06 4.3b 33306 181 2.960.2a,b 121.86 2.1b 25.96 1.9a,b
Palacos R L61 78.26 1.5a,b 74.16 3.4b 32706 137 2.960.2a,b 123.26 1.4b 28.16 3.8a,b
a Significantly different from Palacos R.
b Significantly different from Palacos R1G, ANOVA p< 0.05).
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liposomal Palacos R cements however had higher R-values
than Palacos R1G demonstrating release from the liposomal
cements is more related to diffusion-based mechanisms. The
Korsmeyer–Peppas model was found to best model the Pal-
acos R1G release proﬁle, whilst the Noyes-Whitney dissolu-
tion model ﬁtted the experimental release data for the
liposomal Palacos R cements the best. The R values
obtained from the Noyes–Whitney and the expanded Noyes-
Whitney models were higher for the liposomal Palacos R
cements than the Palacos R1G cements. This demonstrates
a more dissolution-based process taking place in the liposo-
mal Palacos R cements. The additional coefﬁcient (b) was
found to improve the accuracy of the mathematical models
for all the cements tested conﬁrming there was a burst of
antibiotic from the surface of the cement. Interestingly, the
burst coefﬁcient improved the models for Palacos R1G to a
greater extent than the liposomal Palacos R cements.
Agar diffusion assay
Figure 5 shows the zones of inhibition obtained from the
agar diffusion assay and the average radii of the zones. No
zones of inhibition were obtained for Palacos R cement,
demonstrating no antimicrobial activity against S. aureus
[Figure 5(b)]. Palacos R1G was found to produce the larg-
est zone of inhibition in one sample, however the variation
between samples was large, potentially due to variable dis-
persion of the gentamicin sulfate in the cement and/or poor
release properties [Figure 5(c)]. The liposomal Palacos R
cements (L31, L43, and L61) however produced consistent
inhibition zones demonstrating reliable antimicrobial activ-
ity against S. aureus [Figure 5(d–f)]. Furthermore, these
results highlight the availability of the encapsulated genta-
micin sulfate to inhibit S. aureus growth.
Mechanical properties, fracture toughness, glass
transition temperature and hardness
The mechanical properties, fracture toughness, glass transi-
tion temperature and hardness of Palacos R, Palacos R1G
and the liposomal Palacos cements with L31, L43, and
L61 Pluronics are shown in Table III. Palacos R1G had a
signiﬁcantly lower compressive strength, bending modulus,
bending strength and glass transition temperature when
compared to Palacos R cement. This may be due to the
weakening effect of the gentamicin sulfate particles. The lip-
osomal Palacos R cements all experienced a signiﬁcant
reduction in compressive strength when compared to both
Palacos R and Palacos R1G cements. Interestingly, the bend-
ing strength, fracture toughness and Vickers hardness of all
the liposomal Palacos R cements were signiﬁcantly
improved when compared to the Palacos R and Palacos
R1G cement samples. This demonstrates that the well-
dispersed sub-micron liposomes are having a positive effect
on the toughness of the cement. Similarly, the liposomes
were found to increase the glass transition temperature of
the cement.
Fatigue
Figure 6 shows the fatigue crack propagation results for Pal-
acos R, Palacos R1G and the liposomal Palacos R cements
with L31, L43, and L61 Pluronics and Table IV shows the
fatigue test constants obtained when the Paris law was
applied to the fatigue data. All three liposomal Palacos R
cements performed similarly in terms of crack growth rates.
Palacos R1G had a higher rate of crack growth when com-
pared to Palacos R, demonstrating the addition of gentami-
cin sulfate powder to bone cement reduces the crack
resistance of the cement. Interestingly, the addition of well-
dispersed 100 nm liposomes to the cement increased the
fatigue crack growth resistance of the cement. Higher stress
intensities were required to propagate crack growth in the
liposomal cement samples and lower rates of crack growth
(da/dN) were observed. When applying the Paris law to the
fatigue data, the variables ‘A’ and “m” are obtained, where
“A” is the crack growth rate at a stress intensity of 1
MPam1/2 and “m” is the slope of the plot. The rate of crack
growth at 1 MPam1/2 was increased as a result of using
gentamicin sulfate powder in the cement, however the use
of sub-micron liposomes was found to reduce the crack
growth rates of the cement.
Scanning electron microscopy
Figure 7 shows representative SEM images of the fracture
surfaces of the fatigue samples of Palacos R [Figure 7(a)],
Palacos R1G [Figure 7(b)] and the liposomal Palacos R
cements with L31, L43 and L61 Pluronics [Figure 7(c–e),
respectively]. All cements were found to have porosity due
FIGURE 6. Fatigue crack propagation test results for Palacos R, Pala-
cos R1G and the liposomal Palacos R cements. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.
com.]
TABLE IV. Fatigue Test Constants Obtained When Applying
the Paris Law to the Fatigue Data, Where A is the Crack
Growth Rate at 1 MPam1/2 and m is the Slope of the Plot
A m
Correlation
Coefficient
Palacos R 3.73 3 10207 4.65 0.67
Palacos R1G 2.62 3 10206 5.01 0.81
Palacos R L31 8.50 3 10208 5.39 0.72
Palacos R L43 2.68 3 10208 4.85 0.61
Palacos R L61 4.45 3 10208 6.47 0.72
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to air entrapped during mixing and cleaving of PMMA beads
during fracture. The liposomal Palacos R cements were
found to have smaller sized pores (20–50 lm), whilst Pala-
cos R1G had larger pores (50–100 lm). Closer inspection
of the liposomal Palacos R cements found small well-
dispersed pores (<10 lm) throughout the fracture surface.
Rough fracture surfaces were also observed for the liposo-
mal Palacos R cements, indicating non-brittle fracture.
SEM images of the surface of the samples used at the
end of the antibiotic release study (Figure 8) showed that
Palacos R1G had 50–200 lm pores on the surface of the
cement [Figure 8(b)]. Close examination of the surface of
the liposomal Palacos R cements revealed small well-
dispersed pores (<10 lm), as found in the fracture surfaces
[Figure 8(c–e)].
DISCUSSION
Commercially available antibiotic-loaded bone cements, such
as Palacos R1G, employ large amounts of gentamicin sulfate
powder to achieve therapeutic levels of release (from 0.5 to
FIGURE 7. SEM images of the fatigue fracture surfaces for (a) Palacos R, (b) Palacos R1G and liposomal Palacos R with Pluronics (c) L31, (d)
and (e) L61. Arrows indicate PMMA beads, pores and microcracks. [Color figure can be viewed in the online issue, which is available at wileyon-
linelibrary.com.]
FIGURE 8. Surface SEM images of the antibiotic release samples after 1440 hr incubation for (a) Palacos R, (b) Palacos R1G and liposomal Pala-
cos R with Pluronics (c) L31, (d) L43 and (e) L61. Arrows indicate radiopacifier agglomerations and pores. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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1 g per 40 g of cement). Although these cements have
reduced infection rates in cemented joint replacements,
there are several limitations associated with this delivery
system, as shown in this study. A large dose of the antibiotic
is released in an uncontrolled manner from the surface of
the cement within the ﬁrst 6 hr, after which, lower, possibly
sub-inhibitory levels, are released over prolonged periods of
time. This may promote the evolution of resistant bacteria.17
Although large amounts of gentamicin sulfate are incorpo-
rated in commercial cements, only a small percentage (9%
over 60 days) is released, leaving the majority of the antibi-
otic unused in the bulk of the cement. Large amounts of
powdered gentamicin in bone cements have been shown to
affect mechanical and fatigue properties in previous stud-
ies,13–16 with no beneﬁcial inﬂuence against the formation
of bioﬁlms.38,39 Furthermore, the poor dispersion of genta-
micin sulfate in bone cement can result in poor antimicro-
bial activity. With these limitations in mind, there is a clear
requirement to improve antibiotic-loaded cements.
This study demonstrates that liposomes with an encap-
sulated antibiotic can be effectively dispersed in PMMA
bone cement using speciﬁc Pluronics (L31, L43, and L61) as
surfactants. It is hypothesized that the hydrophilic PEO
chains of the Pluronics attach to the outer hydrophilic polar
head groups of the liposome leaving the hydrophobic PPO
chain to interact with a hydrophobic environment, as shown
in Figure 9. This in turn allows the hydrophilic liposomes to
be suspended in a non-aqueous environment such as methyl
methacrylate. TEM and ﬂuorescent microscopy showed that
in the absence of Pluronics, the liposomes aggregated in the
cement, likely due to the hydrophilic outer surfaces of the
liposomes attracting one another in a hydrophobic environ-
ment. The presence of Pluronics on the surface of the lipo-
somes is thought to render the liposome hydrophobic,
enhancing dispersion in non-aqueous environments. When
testing various Pluronic–liposome combinations, it was
observed that hydrophobic Pluronics (with a long PPO
chain) and a low molecular weight (such as Pluronics L31,
L43, and L61) produced the most stable suspensions.25 This
resulted in an even dispersion of liposomes throughout the
cement. All three Pluronics gave similar results in terms of
antibiotic release, antimicrobial efﬁcacy and mechanical,
fatigue and material properties as a result of good disper-
sion properties.
For the liposomal Palacos R cements, there was a small
initial burst of gentamicin sulfate released from the cement
as surface liposomes came into contact with water. The ini-
tial burst of gentamicin sulfate was lower than for the com-
mercial cements as signiﬁcantly less gentamicin sulfate was
employed and fewer agglomerations were present on the
surface. This resulted in a more linear, gradual and pro-
longed release of antibiotic over time from the liposomal
systems. The SEM images of the release samples conﬁrm
this as the commercial cements had randomly located large
pores caused by the release of surface agglomerations of
gentamicin sulfate, whilst the liposomal Palacos R cements
had much smaller well-dispersed pores. The presence of
small well-dispersed pores would promote controlled diffu-
sion of water through the outer layers of the cement. This
in turn would allow water to penetrate uniformly to the
antibiotic below the surface of the cement, resulting in a
more gradual and controlled release; a previous study has
demonstrated PMMA bone cement to absorb moisture over
60 days.40 Large random pores caused by agglomerations of
gentamicin sulfate powder would result in less controlled
release as water penetration into the cement would be less
uniform. The standard deviations for the antibiotic release
from liposomal Palacos R cements were also reduced, dem-
onstrating consistency between the samples tested over the
early time points. Commercial cements on the other hand
demonstrated large standard deviations presumably due to
variability in the levels of antibiotic being released from
each sample.
After 360 hr, the release from the liposomal Palacos R
cements was equal to that of Palacos R1G, despite there
being 60% less gentamicin sulfate in the liposomal Palacos
R cements. This resulted in a much higher percentage
release (11-12% at 72 hr and 21–22% at 1440 hr); more
than double that of Palacos R1G. A recent study using lipo-
somal amphotericin B in Simplex P bone cement obtained
similar improvements over cements with powdered ampho-
tericin B deoxycholate.41
Static release tests were carried out to compare the
release from liposomal Palacos R cements with the release
from Palacos R1G. Although dynamic elution tests would
more accurately replicate in vivo conditions, the static
release test used provides valuable comparative information
on the release of gentamicin sulfate as a result of water
penetration. Results obtained using dynamic elution techni-
ques would subject the cement to a continuous circulation
of medium, which may encourage degradation of the
cement, allowing for increased water penetration and antibi-
otic release. Although Ringer’s solution at 378C replicated
similar temperatures, pH and salt concentrations found in
vivo, the viscosity of the solution differs from blood, which
is increased due to the presence of plasma and particles,
such as red blood cells. In vivo therefore, the penetration of
blood into the cement may differ from that of Ringer’s solu-
tion, resulting in different release rates.
FIGURE 9. Proposed liposome-Pluronics structure. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.
com.]
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Centrifugation of liposomes may not harvest all the lipid
material for inclusion in the MMA, but calculations on gen-
tamicin content have assumed that all the liposomes were
incorporated in cement. Furthermore, a high encapsulation
efﬁciency (nearing 100%) of gentamicin sulfate was also
assumed, however studies have shown the encapsulation
efﬁciency of gentamicin sulfate in liposomes to range from
5 to 40%.42,43 Therefore, the efﬁciency of gentamicin sulfate
release from the liposomal Palacos R cement may be signiﬁ-
cantly greater than the calculated results.
The high efﬁciency of delivery from the liposomal sys-
tem may be attributed to the release mechanisms taking
place. Equations for antibiotic release were used in an
attempt to establish this mechanism. Although simpliﬁed
equations were employed, it was possible to establish the
dominant release mechanism in the cements tested. It is
likely; however, that a combination of mechanisms are
occurring during the release of gentamicin sulfate and
therefore, combining release equations may provide more
accurate models, as demonstrated by Kuhn and Wilson.44
The results from the mathematical models have highlighted
differences between the liposomal Palacos R cements and
Palacos R1G. The poor ﬁt for the Higuchi model highlights
that antibiotic release from bone cement is governed by
more than simple diffusion mechanisms. The release from
liposomal cements are thought to be controlled through a
more diffusion and dissolution based process when com-
pared to Palacos R1G, most likely because the well-
dispersed liposomes create a more controlled pathway for
water to penetrate into the cement. All cements experienced
a burst of release from surface-held antibiotic as demon-
strated by the improved ﬁt in the expanded models. This
improvement was more dramatic for Palacos R1G, demon-
strating Palacos R1G has a greater reliance on surface-
driven release mechanism.
The agar diffusion test demonstrated good bioavailability
of the encapsulated gentamicin sulfate in the liposomal Pal-
acos R cements as reproducible zones of inhibition against
S. aureus were obtained, consistent in both size and shape
between all the liposomal Palacos R samples. Good disper-
sion of the liposomes on the surface layers of cement would
result in an even diffusion of gentamicin sulfate through the
agar, creating consistent zones of inhibition. It can be con-
cluded, therefore, that the liposomal system would most
likely inhibit bacteria in all regions of the cement, unlike
powdered antibiotic based products which were found to
have inconsistent zones of inhibition due to an uneven dis-
tribution of gentamicin sulfate. The efﬁcacy of the liposomal
system was only tested against one strain of bacteria as a
bioindicator. A study by Mugabe et al.45 has shown liposo-
mal delivery of therapeutics to be more effective against
bacteria than free drugs. The mechanism of action of the
liposomes was shown to be through fusion to the wall of
the bacterium. This not only enhanced the antimicrobial
activity of the encapsulated therapeutic but also increased
drug penetration and delivery, making it an exciting method
to combat infections caused by antibiotic-resistant bacteria.
Although the liposomal Palacos R cements were found
to have good release and antimicrobial properties, a reduc-
tion in compressive strength was experienced although this
still remained within the range speciﬁed by international
standards. It is thought that having a dispersion of sub-
micron liposomes in the cement promotes shear yielding,
which occurs near the surface of the material where it is in
plane stress. This reduces the compressive strength but
increases the toughness of the material as observed. A study
using lyophilized liposomes in bone cement also found a
similar reduction in compressive strength.41 The bending
modulus of the liposomal Palacos R cement was not signiﬁ-
cantly different from Palacos R1G. Improvements in bend-
ing strength were observed for the liposomal Palacos R
cement when compared to Palacos R1G. This is due to the
even dispersion of the liposomes which contrasts with the
weakening effect of agglomerations of powdered gentamicin
sulfate. No improvements in bending strength however
were observed when compared to Palacos R cement.
The compression and bending tests were carried out
according to the ISO5833 standard, which all cements must
undergo prior to approval for medical application. The lipo-
somal Palacos R cements were found to exceed the ISO5833
minimum requirements for compression and bending prop-
erties, demonstrating the novel delivery system retains the
suitability of Palacos cement as an acrylic cement for
orthopaedics.
After the release of gentamicin sulfate from the liposo-
mal Palacos R cements, small well-dispersed pores were
observed in the SEM images. It has been hypothesised that
small dispersed pores may be beneﬁcial to mechanical and
fatigue properties by promoting shear yielding ahead of the
crack tip, as well as blunting the crack tip.46,47 Small pores
are also thought to reduce polymerization shrinkage, reduc-
ing the likelihood of residual stress-induced cracks.48 It is
postulated that the sub-micron pores and liposomes in the
liposomal Palacos R cements behave similar to small rubber
particles, inducing toughening mechanisms. Rubber particles
have been shown to improve the fracture toughness of bone
cement through shear yielding, crack deviation and craze
formation,49–51 but reduce compressive strength as yielding
occurs in compression.52,53 Furthermore, rubber particles
have also been shown to reduce the modulus of materials,
as experienced with the liposomal Palacos R cements.54
Toughening through shear yielding mechanisms in the lipo-
somal Palacos R cements was observed due to an increase
in fracture toughness and fatigue crack propagation. The
fracture surfaces were also found to be rougher in the lipo-
somal Palacos R cements, demonstrating non-brittle
fracture.
Tests on the structure of liposomal Palacos R cements
demonstrated that liposomes do not affect the molecular
structure of the cement; however, the hardness of the
cement was signiﬁcantly increased by the addition of lipo-
somes. As hardness value is linked to the yield stress and
toughness of a material, it is expected that the yield stress
of the liposomal Palacos R cements would also be signiﬁ-
cantly higher than Palacos R/R1G. The glass transition
ORIGINAL RESEARCH REPORT
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temperature was also affected, however at temperatures
well below the Tg of the cements (for example, in vivo tem-
peratures of 378C), it is expected that the slight change will
not be detrimental to the mechanical properties as fatigue
testing at 378C was not detrimental to crack growth rates.
The ISO5833 standard used for mechanical testing does not
specify required testing temperatures. Nevertheless, testing
at this temperature would ensure that the changes in Tg
experienced do not signiﬁcantly affect the compression and
bending properties of the liposomal Palacos R cements. Fur-
thermore, creep testing would provide useful information
on the rate of deformation that the novel cement is likely to
undergo in vivo.
CONCLUSION
Liposomes have been successfully incorporated into a com-
mercial PMMA bone cement (Palacos R) and, with the
exception of compressive strength, the commercial cement
properties were not adversely affected. Furthermore, all
cement properties were above the ISO5833 minimum
requirements for acrylic resin cements and the presence of
well-dispersed liposomes throughout the cement improved
the bending, fracture toughness, fatigue and hardness prop-
erties of the commercial cement. It is speculated that the
improvement in fracture toughness and fatigue crack
growth resistance is caused by the dispersed liposomes
inducing rubber toughening mechanisms, such as shear
yielding. The novel drug delivery system demonstrated
enhanced dispersion of antibiotics when compared to the
current powdered antibiotic system. This resulted in a more
controlled, gradual and prolonged release of gentamicin sul-
fate; more consistent antimicrobial properties and higher
efﬁciency, requiring less gentamicin sulfate to achieve thera-
peutic levels of release. It is speculated that the liposome
dispersion allows water to penetrate and diffuse below the
surface of cement in a controlled manner.
Although the initial results are promising, it will now be
essential to study the long-term stability of liposomes in
MMA and determine how liposome modiﬁed bone cements
perform in vivo. The system must also be optimised in
terms of the antibiotics used; in this regard the ability to
employ antibiotics in aqueous solution may broaden the
range of agents ﬁnding application. Further optimization
will include: the size and composition of the liposomes; the
encapsulation efﬁciency and the use of other preparation
methods, such as lyophilization, to ensure optimum release,
antimicrobial, mechanical and fatigue properties in vivo.
In conclusion, the release of liposomal therapeutic
agents from PMMA bone cement may play a vital role in
reducing infection rates and potentially improving osseoin-
tegration in cemented joint replacements and therefore
enhance patient quality of life, whilst reducing costs for
healthcare providers.
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